PRN1371 is primarily utilized in the field of cancer research due to its role as a potent and selective inhibitor of fibroblast growth factor receptor (FGFR). Its application is significant in targeting FGFR-driven cancers, where abnormal FGFR signaling contributes to tumor growth and progression. Researchers employ PRN1371 to study the inhibition of FGFR activity in preclinical models, helping to understand its potential as a therapeutic agent. It is particularly relevant in cancers such as bladder, breast, and lung, where FGFR mutations or amplifications are common. Additionally, PRN1371 is used to investigate resistance mechanisms and combination therapies, aiming to enhance treatment efficacy and overcome limitations in current cancer therapies.